Reversibility of impaired cerebrovascular reactivity in patients with hypertension: comparison of losartan and atenolol

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN77942127

Enrollment

Registered

2005-10-27

Start date

2004-08-01

Completion date

Unknown

Last updated

2016-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension Circulatory System Hypertension

Interventions

Patients will undergo baseline assessment of cerebrovascular reactivity. Mean flow velocity (MFV) in the middle cerebral artery (MCA) will be measured using transcranial Doppler. Each subject will the

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Male: 50-80 years 2. Electrocardiogram (ECG) evidence of left ventricular hypertrophy (LVH) 3. Blood pressure (BP) 150-200/90-115

Exclusion criteria

Exclusion criteria: 1. >70% internal carotid artery (ICA) stenosis 2. Middle cerebral artery (MCA) stenosis 3. Contra-indication to losartan, atenolol or acetazolamide 4. Serum creatinine >130 µmol/l 5. Prior treatment with angiotensin converting enzyme (ACE)-1/angiotensin II receptor blocker (ARB)/beta blocker unless able to stop 4 weeks prior to recruitment

Design outcomes

Primary

Measure	Time frame
Changes in cerebrovascular reactivity.	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026